Observation of probable persistent, undetected trichomonas vaginalis infection among HIV-Positive women

Clinical Infectious Diseases

Volumn 51, Issue 1, 2010, Pages 114-115

  Gatski, Megan ^a   Kissinger, Patricia ^a  

^a TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE;

DRUG TREATMENT FAILURE; FEMALE; FUNGAL DETECTION; FUNGUS CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; PATIENT COMPLIANCE; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REINFECTION; SEXUAL BEHAVIOR; TRICHOMONAS VAGINALIS; TRICHOMONIASIS;

FALSE NEGATIVE REACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TRICHOMONAS INFECTIONS; TRICHOMONAS VAGINALIS;

EID: 77953786130     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653443     Document Type: Letter

References (6)

1. Peterman TA, Tian LH, Metcalf CA, et al. Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis 2009;48(2):259-260.
2. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: 2 gram STAT versus 7 day 500 mg BID dose of metronidazole (MTZ) for the treatment of Trichomonas vaginalis among HIV-infected women. Paper presented at: National STD Prevention Conference; March 8-11, 2010; Atlanta, GA.
3. McClelland RS, Sangare L, Hassan WM, et al. Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition. J Infect Dis 2007; 195(5):698-702.
4. Sorvillo F, Kerndt P. Trichomonas vaginalis and amplification of HIV-1 transmission. Lancet 1998;351(9097):213-214.
5. Sorvillo F, Smith L, Kerndt P, Ash L. Trichomonas vaginalis, HIV, and African Americans. Emerg Infect Dis 2001;7(6):927-932.
6. Laga M, Manoka A, Kivuvu M, et al. Nonulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993; 7(1):95-102.